PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Endocyte Announces First Quarter 2017 Earnings Conference Call
WEST LAFAYETTE, Ind. , May 03, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. , (NASDAQ:ECYT) announced today that the company will host a conference call on Wednesday, May 10th , at 8:30 a.m. EDT to discuss its first quarter financial results and provide an operational update.
View HTML
Toggle Summary Endocyte Presents Data at AACR Identifying Multiple Methods for Managing Severe Side Effects Resulting from CAR T-Cell Treatment
- Late-breaking poster demonstrates that Endocyte's bi-specific adaptor molecules can mitigate or eliminate cytokine storms - - Potential to meaningfully improve the safety and tolerability of CAR T-cell therapies - WEST LAFAYETTE, Ind. , April 05, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc.
View HTML
Toggle Summary Endocyte Announces Presentations at American Association for Cancer Research (AACR) Annual Meeting 2017
--Presentations to include late-breaker highlighting Endocyte's next generation CAR T-cell therapeutic platform—
View HTML
Toggle Summary Endocyte Reports Fourth Quarter and Year End 2016 Financial Results and Provides Clinical and Pipeline Update
Conference Call Today at 8:30 a.m. EST
View HTML
Toggle Summary Endocyte and Seattle Children's Research Institute to Collaborate on Endocyte's Small Molecule Drug Conjugate Bi-Specific Adaptor Molecules for CAR T-cell Therapies
Collaboration pairs leading SMDC technology with recognized CAR T-cell research expert Plans to develop next generation CAR T-cell therapeutic platform with potential for improved safety and efficacy in solid tumor indications WEST LAFAYETTE, Ind. , March 10, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc.
View HTML
Toggle Summary Endocyte Announces Fourth Quarter and Full Year 2016 Earnings Conference Call
WEST LAFAYETTE, Ind. , March 02, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. , (NASDAQ:ECYT) announced today that the company will host a conference call on Friday, March 10th , at 8:30 a.m. EST to discuss its fourth quarter and full year financial results and provide an operational update.
View HTML
Toggle Summary Endocyte to Present at the Cowen and Company 37th Annual Health Care Conference
WEST LAFAYETTE, Ind. , March 01, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company's management team will present at the Cowen and
View HTML
Toggle Summary Endocyte Appoints Michael T. Andriole as Chief Financial Officer
WEST LAFAYETTE, Ind. , Feb. 21, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that Michael T. Andriole has been appointed as chief financial
View HTML
Toggle Summary Endocyte to Present at the IASLC 17th World Conference on Lung Cancer
WEST LAFAYETTE, Ind. , Dec. 01, 2016 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that data from ongoing phase 1 trials of Endocyte's SMDC EC1456 will
View HTML
Toggle Summary Endocyte Reports Third Quarter 2016 Financial Results
- Confirmed Maximum Dose for EC1169 and Initiated Expansion Phase in Prostate Cancer Patients - - First Confirmed RECIST Partial Response Observed in EC1169 Dose Escalation Reported at European Society for Medical Oncology (ESMO) in October - - Conference Call Today at 4:30 p.m.
View HTML